Fabian Lang

10PUBLICATIONS
44CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)HaematologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 02, 2026
Efficacy of imatinib maintenance after stem cell transplantation for Ph+/BCR::ABL1 positive ALL: long-term outcome of a randomized trial and impact of peritransplant minimal residual disease.

|Jul 16, 2026
Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results.

|Mar 22, 2026
Spinal cord disease following CAR T-cell therapy with axicabtagene ciloleucel in a patient with high-grade B-cell lymphoma.

Clara Walter, Michael C Burger, Kai Siebenbrodt

|Jul 30, 2025
Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial.

Matthias Stelljes, Jan Moritz Middeke, Gesine Bug

|Apr 09, 2025
Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results.

Jorge E Cortes, Fabian Lang, Delphine Rea

|Apr 09, 2025
Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results.

Andreas Hochhaus, Dong-Wook Kim, Jorge E Cortes

Pageof 2

Frequent Collaborators

3 joint publications

Michael C Heinrich

3 joint publications

Daniel J DeAngelo

3 joint publications

Andreas Hochhaus

3 joint publications

Jorge E Cortes